HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Frame, D. Search for Related Content PubMed PubMed Citation Articles by Frame, D.

DAVID FRAME, PHARM.D., is Clinical Assistant Professor of Pharmacy, University of Michigan Hospital, Department of Pharmacy UHB2D301, 1500 East Medical Center Drive, Ann Arbor, MI 48109 (dframe{at}med.umich.edu).

Purpose. Treatment options for chronic myeloid leukemia (CML) are discussed. Summary. In the 1980s busulfan and hydroxyurea were the standards of care. These were subsequently replaced by interferon (IFN ) based therapy. Currently, bone marrow transplant survival has improved, making this also a viable option. Five-year progression-free survival averaged above 70% for chemotherapeutic options. Transplant survival at 56 months was approximately 60%; however, these survivors were generally cured of disease. The recognition of the role for BCR-ABL in CML has led to the development of specific kinase inhibitors such as imatinib. Clinical trial evidence has demonstrated a clear superiority of imatinib over interferon plus cytarabine, making this the new standard of care in first-line treatment of CML. Resistance to imatinib has been observed, in addition to relapse. The data suggest that the probability of response may be estimated as early as six months after initiation of imatinib therapy. Although combinations of imatinib with IFN show small improvements compared to imatinib therapy alone, the biggest improvements were seen when imatinib doses were doubled. Unfortunately, not all patients can tolerate this increase in dose. The most common mechanism for imatinib resistance is the presence of a mutated BCR-ABL kinase. Several of these mutants have been cloned and characterized. Conclusion. Molecular-targeted BCR-ABL kinase inhibitors, such as imatinib, are now first-line treatment for CML. Allogeneic stem cell transplant is still the only proven curable treatment for CML in patients with an appropriate donor. Next generation BCR-ABL kinase inhibitors hold promise for patients with mutated BCR-ABL kinase that confer resistance to imatinib. Index terms: Antineoplastic agents; Busulfan; Combined therapy; Cytarabine; Dosage; Hydroxyurea; Imatinib; Interferon alfa; Leukemia; Mechanism of action; Resistance; Site of action; Toxicity; Transplantation